Agios Pharmaceuticals (AGIO) Other financing activities (2012 - 2026)

Agios Pharmaceuticals' Other financing activities history runs 15 years deep, the most recent figure standing at $2.1 million for Q1 2026.

• Quarterly Other financing activities rose 28.35% year-over-year to $2.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.1 million (down 10.41% YoY) and the FY2025 annual result came in at $8.7 million, down 39.93% from the prior year.
• Other financing activities was $2.1 million for Q1 2026 at Agios Pharmaceuticals, down from $2.6 million in the prior quarter.
• Across five years, Other financing activities topped out at $5.9 million in Q1 2024 and bottomed at $16000.0 in Q2 2022.
• A 5-year average of $2.0 million and a median of $1.6 million in 2025 frame the typical range for Other financing activities.
• Annual changes were most pronounced in 2022 — Other financing activities plunged 96.57% — and 2023, when it surged 1381.25%.
• Agios Pharmaceuticals' Other financing activities stood at $105000.0 in 2022, then surged by 706.67% to $847000.0 in 2023, then soared by 471.66% to $4.8 million in 2024, then tumbled by 47.19% to $2.6 million in 2025, then dropped by 18.73% to $2.1 million in 2026.
• Business Quant data shows AGIO's Other financing activities at $2.1 million in Q1 2026, $2.6 million in Q4 2025, and $4.4 million in Q3 2025.